查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048302

夫西地酸市場－全球產業規模、佔有率、趨勢、機會、預測：銷售管道、最終用途、地區和競爭格局（2021-2031年）

Fusidic Acid Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel (Direct, Indirect), By End Use (Impetigo, Cellulitis, Cuts & Wounds, Eye Infection, Others), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球夫西地酸市場預計將從 2025 年的 3,112 萬美元成長到 2031 年的 3,527 萬美元，複合年成長率為 2.11%。

這種源自鐮刀菌（Fusidium coccineum）的抑菌抗生素主要用於治療金黃色葡萄球菌引起的皮膚和軟組織感染疾病。全球範圍內膿皰瘡和感染性濕疹等皮膚疾病的增加推動了市場成長，這些疾病需要特定的抗菌治療。人口老化加劇了慢性皮膚傷口和細菌併發症的發生，也進一步刺激了市場需求。例如，根據美國皮膚病學會預測，到2025年，近十分之一的美國人將患有異位性皮膚炎，這將導致人們對局部抗生素的持續依賴。然而，抗生素抗藥性的日益增強阻礙了市場擴張。對夫西地酸敏感性降低的菌株的出現，促使醫療機構實施更嚴格的合理抗菌藥物使用（ASM）指南並限制處方療程，醫療專業人員也對長期用藥更加謹慎。這種對藥物使用進行規範的需求構成了結構性障礙，限制了產品的普及和無限成長的潛力。

市場概覽
預測期 2027-2031
市場規模：2025年 3112萬美元
市場規模：2031年 3527萬美元
複合年成長率：2026-2031年 2.11%
成長最快的細分市場 直接地
最大的市場 亞太地區

市場促進因素

市場的主要促進因素是全球細菌性皮膚感染疾病的日益普遍，這促使人們更需要獲得有效的局部抗生素。由於膿皰瘡和繼發性感染性皮膚炎等疾病導致皮膚屏障功能受損的病例不斷增加，使得臨床上越來越依賴夫西地酸的靶向抑菌作用。這種成長趨勢在年輕人中尤其明顯，由於環境因素和免疫系統發育不完善，他們更容易受到細菌侵襲。 BMC Pediatrics預測，到2025年6月，全球兒童和青少年皮膚感染病例將達到3.38億例。患者數量的增加與夫西地酸處方量的增加直接相關，鞏固了其作為治療併發症皮膚感染疾病的主要藥物的地位。此外，抗藥性金黃色葡萄球菌（MRSA）感染率的上升也推動了對能夠克服BETA-內醯胺類抗生素抗藥性的替代抗生素的需求激增。夫西地酸仍然是抗藥性金黃色葡萄球菌聯合治療和特定區域治療方案中的重要組成部分，在標準青黴素類藥物治療無效時發揮關鍵的防禦作用。耐甲氧西林金黃色葡萄球菌（MRSA）在社區和醫院環境中的持續存在，推動了對多種抗生素的需求，並維持了市場成長動能。例如，丹麥國家血清研究所2025年2月發布的EPI-NEWS報告指出，MRSA新病例年增22%，這推動了治療方法的多樣化，並增強了現有治療方法的商業性韌性。這點也反映在利奧製藥公司（LEO Pharma）預計2025年皮膚科產品組合銷售額將成長9%的預測。

市場挑戰

抗生素抗藥性的日益嚴重是全球夫西地酸市場商業性擴張的一大結構性障礙。由於某些細菌菌株對這種抗生素的敏感性降低，監管機構和醫療機構正在實施嚴格的抗菌藥物使用方案。這些措施正在重塑市場格局，將夫西地酸從常規的一線治療藥物重新歸類為使用範圍較窄的治療選擇。這種監管轉變迫使醫生限制處方頻率和療程以維持藥物療效，直接限制了產品銷售量並抑制了收入潛力，儘管相關皮膚疾病的發生率很高。抗藥性感染疾病的不斷增加凸顯了這項挑戰的嚴峻性，也使得這種嚴格的管控成為必要。例如，英國衛生安全局報告稱，2024年抗生素抗藥性菌血症病例增加了9.3%，證明了醫療專業人員謹慎行事的合理性，並造成了持續的瓶頸，阻礙了夫西地酸產品的推廣應用和整個行業的成長。

市場趨勢

由於與皮質類固醇具有協同作用的聯合治療日益普及，全球夫西地酸市場格局正經歷重大重組。製造商正日益專注於將夫西地酸與強效抗發炎藥物（如Betamethasone和Hydrocortisone）聯合使用的固定劑量製劑，以同時控制細菌生長和與感染性異位性皮膚炎相關的潛在發炎。此趨勢的驅動力源自於臨床上提高患者依從性和治療效果的需求，即簡化易發生繼發性感染疾病的多管治療方法。擁有強大雙效療法產品組合的市場領導證明了這種標靶皮膚病學方法的商業性成功。例如，LEO Pharma的皮膚病學銷售額預計在2024年年增12%，凸顯了全球對皮膚病學綜合感染疾病管理解決方案的持續需求。同時，新興市場（尤其是印度和東南亞）的學名藥生產能力正在迅速擴張。這一趨勢涉及生產的策略多元化，即本土製藥公司擴大產能以滿足國內需求，並成為全球供應鏈中具有成本效益的出口樞紐。這種轉變使製造商能夠利用人口稠密地區不斷成長的處方量，同時避免歐美市場的高昂營運成本。這些區域製造地的快速成長正在挑戰現有的定價結構，並提高產品供應量。例如，Glenmark Pharmaceuticals在印度的製劑業務在2025年第三季實現了300.2%的年成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球岩藻酸市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 銷售管道（直接、間接）
    • 依用途分類（膿皰瘡、蜂窩組織炎炎、割傷/傷口、眼部感染疾病、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美岩藻酸市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲岩藻酸市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區夫氏酸市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲地區夫西酸市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美富馬酸市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球夫西吉酸市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Ercros SA
  • Emote Life sciences LLP
  • Kaniwa Bioscience Pvt. Ltd
  • Concord Biotech Limited
  • Fleming Laboratories Ltd
  • Sterling Biotech Ltd
  • Oliver Pharmaceuticals
  • Apex Healthcare Ltd
  • Horster Life Sciences Pvt. Ltd.
  • Celaxis Bioscience Pvt Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28286

The global fusidic acid market is projected to expand from USD 31.12 million in 2025 to USD 35.27 million by 2031, at a CAGR of 2.11%. This bacteriostatic antibiotic, derived from Fusidium coccineum, is primarily used for skin and soft tissue infections caused by Staphylococcus aureus. Market growth is driven by the increasing global prevalence of dermatological conditions like impetigo and infected eczema, which necessitate specific antimicrobial treatments. An aging population, more susceptible to chronic skin wounds and bacterial complications, further boosts demand; for instance, atopic dermatitis affected nearly one in ten Americans in 2025, according to the American Academy of Dermatology, creating sustained reliance on topical antibiotics. Nevertheless, the market's expansion is hindered by growing antimicrobial resistance. The development of bacterial strains less responsive to fusidic acid has led medical authorities to implement stricter antimicrobial stewardship and limit prescription durations, causing healthcare providers to be cautious regarding prolonged use. This necessity for regulated application acts as a structural barrier, limiting product adoption and potential for unrestricted volume growth.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 31.12 Million
Market Size 2031USD 35.27 Million
CAGR 2026-20312.11%
Fastest Growing SegmentDirect
Largest MarketAsia Pacific

Market Driver

A primary market driver is the increasing global prevalence of bacterial skin infections, which demands widespread access to effective topical antibiotics. Conditions such as impetigo and secondary infected dermatitis are increasingly compromising the skin barrier, intensifying clinical reliance on fusidic acid's targeted bacteriostatic action. This rise is notable in younger populations, more prone to skin bacterial invasions due to environmental factors and developing immune systems, with global incidence among children and adolescents reaching 338 million cases by June 2025, according to BMC Pediatrics. This growing patient base directly correlates with higher fusidic acid prescriptions, establishing it as a key therapeutic for uncomplicated dermatological infections. Additionally, the rising incidence of Methicillin-Resistant Staphylococcus Aureus (MRSA) creates critical demand for alternative antimicrobials that can overcome beta-lactam resistance. Fusidic acid remains a vital component in combination therapies and specific regional treatment protocols for resistant staphylococcal strains, providing a crucial defense when standard penicillin-based treatments fail. The ongoing presence of MRSA in community and hospital settings necessitates diverse antibiotic classes, sustaining market momentum. For instance, the Statens Serum Institut's February 2025 'EPI-NEWS' report noted a 22% year-over-year increase in new MRSA cases, driving therapeutic diversification and reinforcing the commercial resilience of established treatments, as evidenced by LEO Pharma's 9% dermatology portfolio revenue growth in 2025.

Market Challenge

The escalation of antimicrobial resistance poses a significant structural barrier to the global fusidic acid market's commercial expansion. As certain bacterial strains develop reduced susceptibility to this antibiotic, regulatory bodies and healthcare organizations are implementing stringent antimicrobial stewardship programs. These initiatives are reshaping the market by reclassifying fusidic acid from a routine first-line treatment to a more restricted therapeutic option. This regulatory change compels physicians to limit prescription frequency and duration to maintain the drug's effectiveness, directly constraining product volume and capping revenue potential despite the high incidence of relevant skin conditions. The severity of this challenge is underscored by the rising occurrence of resistant infections, necessitating these strict controls. For example, the UK Health Security Agency reported a 9.3% increase in bacteraemia cases caused by antibiotic resistance in 2024, validating the cautious approach by medical professionals and creating a persistent bottleneck that impedes fusidic acid product adoption and overall sector growth.

Market Trends

The global fusidic acid market's therapeutic landscape is being significantly reshaped by the proliferation of synergistic combination therapies with corticosteroids. Manufacturers are increasingly focusing on fixed-dose formulations that blend fusidic acid with potent anti-inflammatory agents, such as betamethasone or hydrocortisone, to simultaneously manage bacterial growth and the underlying inflammation associated with infected atopic dermatitis. This trend is driven by the clinical need to improve patient compliance and treatment effectiveness by simplifying multi-tube regimens for conditions prone to secondary infections. The commercial success of this targeted dermatological approach is demonstrated by market leaders with strong portfolios of these dual-action therapies; for example, LEO Pharma's dermatology revenue increased by 12% year-over-year in 2024, highlighting sustained global demand for integrated infection-management solutions in dermatology. Concurrently, there is rapid expansion of generic manufacturing capabilities in emerging markets, especially India and Southeast Asia. This trend involves a strategic decentralization of production, where local pharmaceutical companies scale up capacities to meet domestic needs and serve as cost-effective export hubs for the global supply chain. This shift enables manufacturers to bypass high operational costs of Western markets while capitalizing on growing prescription volumes in densely populated regions. The rapid growth of these regional manufacturing bases challenges existing pricing structures and enhances product accessibility, as shown by Glenmark Pharmaceuticals' India formulation business registering 300.2% year-over-year growth in Q3 2025.

Key Market Players

  • Ercros S.A
  • Emote Life sciences LLP
  • Kaniwa Bioscience Pvt. Ltd
  • Concord Biotech Limited
  • Fleming Laboratories Ltd
  • Sterling Biotech Ltd
  • Oliver Pharmaceuticals
  • Apex Healthcare Ltd
  • Horster Life Sciences Pvt. Ltd.
  • Celaxis Bioscience Pvt Ltd

Report Scope

In this report, the Global Fusidic Acid Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fusidic Acid Market, By Sales Channel

  • Direct
  • Indirect

Fusidic Acid Market, By End Use

  • Impetigo
  • Cellulitis
  • Cuts & Wounds
  • Eye Infection
  • Others

Fusidic Acid Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fusidic Acid Market.

Available Customizations:

Global Fusidic Acid Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Fusidic Acid Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Impetigo, Cellulitis, Cuts & Wounds, Eye Infection, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Fusidic Acid Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Fusidic Acid Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Fusidic Acid Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Fusidic Acid Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Fusidic Acid Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Fusidic Acid Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Fusidic Acid Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Fusidic Acid Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Fusidic Acid Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Fusidic Acid Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Fusidic Acid Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Fusidic Acid Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Fusidic Acid Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Fusidic Acid Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Fusidic Acid Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Fusidic Acid Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Fusidic Acid Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Fusidic Acid Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Fusidic Acid Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Fusidic Acid Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. South America Fusidic Acid Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Fusidic Acid Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Fusidic Acid Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Fusidic Acid Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Fusidic Acid Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Ercros S.A
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Emote Life sciences LLP
  • 15.3. Kaniwa Bioscience Pvt. Ltd
  • 15.4. Concord Biotech Limited
  • 15.5. Fleming Laboratories Ltd
  • 15.6. Sterling Biotech Ltd
  • 15.7. Oliver Pharmaceuticals
  • 15.8. Apex Healthcare Ltd
  • 15.9. Horster Life Sciences Pvt. Ltd.
  • 15.10. Celaxis Bioscience Pvt Ltd

16. Strategic Recommendations

17. About Us & Disclaimer